



ASX ANNOUNCEMENT

Share Purchase Plan – Offer Documents

Melbourne, Australia; 22 November, 2011: Attached is documentation to be mailed to shareholders regarding the Share Purchase Plan (SPP) announced by Starpharma Holdings Limited (ASX:SPL; OTCQX:SPHRY) on 16 November 2011.

Australian and New Zealand registered shareholders who held shares at 7pm AEDT on the record date of 15 November 2011 are eligible to participate in the SPP.

The SPP opens on 23 November 2011 and will close at 5pm AEDT on Wednesday 7 December 2011.

ABOUT STARPHARMA

Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY) is a world leader in the development of dendrimer technology for pharmaceutical, life-science and other applications. SPL has two operating companies, Starpharma Pty Ltd in Melbourne, Australia and DNT, Inc in the USA. Products based on SPL's dendrimer technology are already on the market in the form of diagnostic elements and laboratory reagents through licence arrangements with partners including Siemens and Merck KGaA.

The Company's lead pharmaceutical development product is VivaGel[®] (SPL7013 Gel), a vaginal microbicide designed to prevent the transmission of STIs, including HIV, genital herpes and bacterial vaginosis. Starpharma has a licence agreement with Ansell Limited to develop a VivaGel[®]-coated condom, and a licence agreement with Okamoto Industries Inc in relation to the VivaGel[®]-coated condom for the Japanese market. Okamoto is the market leader for condoms sold in Japan, the world's second largest condom market.

Starpharma also has agreements in place with Lilly, Elanco, Stiefel Laboratories (a GSK Company), and Siemens Healthcare as well as many research collaborations with some of the world's leading organisations in the fields of pharmaceuticals, drug delivery, cosmetics and agrochemicals.

A dendrimer is a type of precisely-defined, branched nanoparticle. Dendrimers have applications in the medical, electronics, chemicals and materials industries.

American Depository Receipts (ADRs): Starpharma's ADRs trade under the code **SPHRY** (CUSIP number 855563102). Each Starpharma ADR is equivalent to 10 ordinary shares of Starpharma as traded on the Australian Securities Exchange (ASX). Starpharma's ADRs are listed on International OTCQX, a premium market tier in the U.S. for international exchange-listed companies.

FOR FURTHER INFORMATION

Media:

Buchan Consulting

Rebecca Wilson

Mob: +61 417 382 391

rwilson@buchanwe.com.au

Haley Price

Mob: +61 423 139 163

hprice@buchanwe.com.au

Starpharma:

Dr Jackie Fairley, Chief Executive Officer

+61 3 8532 2704

Ben Rogers, Company Secretary

+61 3 8532 2702

ben.rogers@starpharma.com

www.starpharma.com

Forward Looking Statements

This document contains certain forward-looking statements, relating to Starpharma's business, which can be identified by the use of forward-looking terminology such as "promising", "plans", "anticipated", "will", "project", "believe", "forecast", "expected", "estimated", "targeting", "aiming", "set to", "potential", "seeking to", "goal", "could provide", "intends", "is being developed", "could be", "on track", or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA's and other health authorities' requirements regarding any one or more product candidates nor can there be any assurance that such product candidates will be approved by any health authorities for sale in any market or that they will reach any particular level of sales. In particular, management's expectations regarding the approval and commercialization of the product candidates could be affected by, among other things, unexpected clinical trial results, including additional analysis of existing clinical data, and new clinical data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. Starpharma is providing this information as of the date of this document and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.



22 November 2011

Dear Shareholder,

2011 Share Purchase Plan

Following the successful capital raising of A\$32 million through a private placement to existing and new institutional and sophisticated investors (**Placement**), the Board of Directors of Starpharma Holdings Limited (**Starpharma**) is pleased to offer eligible shareholders the opportunity to subscribe for new ordinary shares in Starpharma by way of a share purchase plan (**SPP**).

The offer price under the SPP is A\$1.075 per share, the same issue price as the shares issued under the Placement. This issue price represents a 1.64% discount to the volume weighted average market price of Starpharma shares traded in the ordinary course on ASX during the 5 trading days prior to the day on which the SPP was announced.

The Placement was conducted at the last closing price prior to Trading Halt (A\$1.075 per share), and was significantly oversubscribed. There was strong participation in the Placement from existing institutions including large global funds and local investors. The Company is also pleased to welcome to the register a major new international institution which will become a significant shareholder via the Placement.

Funds raised will be used to accelerate and complete both VivaGel[®] Bacterial Vaginosis Phase 3 Programs (Treatment, and Prevention of Recurrence) supporting an NDA filing and commercial licence, as well as allowing the company to advance multiple product opportunities across its drug delivery and agrochemical programs.

2011 has seen major advances in all three of Starpharma's key strategic focus areas – VivaGel[®], drug delivery and agrochemicals. This capital raising changes the course of the company in terms of our ability to advance these more rapidly in parallel to optimise commercial outcomes. We see the outstanding response to this Placement as validation of the significant value of our dendrimer platform, the growing maturity of Starpharma's business, and the increasing commercial momentum across multiple product applications.

As set out in our ASX announcement on 16 November 2011, the proceeds from the institutional placement and SPP will be used as follows:

Activity	
1. Accelerate two VivaGel [®] Bacterial Vaginosis Phase 3 Programs, file NDA and negotiate late stage licence	\$16 million
2. Advance Internal Drug Delivery Program into clinical development	\$8.5 million
3. Accelerate Agrochemical & Other Programs	\$5 million
4. Working Capital	\$5.5 million
Total (\$32 million Placement and \$3 million SPP)	\$35.0 million

Under the SPP, you can subscribe for up to A\$15,000 worth of new Starpharma ordinary shares without paying any brokerage. The SPP will be capped at A\$3 million and Starpharma will scale back Applications if they exceed A\$3 million in aggregate. If Applications are scaled back, Starpharma reserves the right to undertake the scale back in any manner it considers fit.

Australian and New Zealand registered shareholders who held shares at 7:00pm (AEDT) on the record date of 15 November 2011 are eligible to participate in the SPP. The SPP closes at 5:00pm AEDT on 7 December 2011.

The Board encourages you to carefully read the enclosed SPP offer document and application form, before making your investment decision.

On behalf of the Board, I thank you for your continued support as a Starpharma shareholder.

Yours sincerely,



Jackie Fairley
Director and Chief Executive Officer

Starpharma Holdings Limited

2011 Share Purchase Plan

Starpharma Holdings Limited ACN 078 532 180 (**Starpharma**) is pleased to provide Eligible Shareholders (see section 6 below) with the opportunity to participate in Starpharma's 2011 Share Purchase Plan (**SPP**) by subscribing for up to \$15,000 of new fully paid ordinary shares (**New Shares**) in Starpharma (**Offer**).

The price for each New Share is \$1.075.

Details of the Offer and how to participate are set out in this Offer Document.

You may contact Starpharma's Share Registry, Computershare Investor Services Pty Limited, on 1300 850 505 (within Australia) or +61 3 9415 4000 (outside Australia) if you have any queries in relation to the SPP.

1. Background

On 16 November 2011, Starpharma announced that it had completed a placement of Shares to international and domestic institutional, sophisticated and professional investors to raise \$32 million at \$1.075 per Share (**Placement**).

At the same time as it announced the Placement, Starpharma announced that it would raise up to an additional \$3 million through the issue of up to 2.79 million New Shares to Eligible Shareholders under an SPP priced at \$1.075 per New Share, the same issue price as that offered under the Placement.

For current information on Starpharma, shareholders are referred to the 2011 Annual Report and to recent announcements lodged with ASX. These documents can be found on Starpharma's website at www.starpharma.com or on the ASX website at www.asx.com.au (ASX code: SPL).

2. Key Dates

Key dates for the SPP are as follows (all times are AEDT).

Indicative Timetable*	
Record Date	7:00pm, 15 November 2011
Opening Date	23 November 2011
Closing Date	5:00pm, 7 December 2011 (unless extended)
Allotment of New Shares	14 December 2011
Trading of New Shares expected to commence on ASX	15 December 2011
Holding statements expected to be dispatched to shareholders	16 December 2011

* These dates are indicative only and subject to change. Starpharma reserves the right to amend this indicative timetable without notice. In particular, Starpharma reserves the right, subject to the Corporations Act and the Listing Rules to close the Offer early, to extend the Closing Date or to withdraw the Offer without prior notice. Any extension of the Closing Date will have a consequential effect on the date for the issue of New Shares.

3. Price and allocation

The price payable for each New Share under the SPP will be \$1.075, being the price at which Shares were issued under the Placement.

The issue price represents a 1.64% discount to the volume weighted average market price of Shares traded in the ordinary course on ASX during the 5 trading days prior to the day on which the SPP was announced.

The Offer under the SPP is being made in accordance with the disclosure relief granted by ASIC under CO 09/425. Under CO 09/425, the maximum value of New Shares each Eligible Shareholder may subscribe for is \$15,000.

Under the SPP, you may apply for a parcel of New Shares in the amount of \$1,000, \$2,500, \$5,000, \$7,500, \$10,000, \$12,500 or \$15,000. Starpharma will deal with Applications that are not made in these amounts in accordance with condition 8.1.

In the absence of a scale back (see section 7), the number of New Shares to be issued to you will be calculated by dividing your Application amount by the offer price (\$1.075) then rounding up to the nearest whole number of New Shares.

Accordingly, the number of New Shares that will be issued for each Application amount are as follows.

Application Amount	New Shares
\$1,000	931
\$2,500	2,326
\$5,000	4,652
\$7,500	6,977
\$10,000	9,303
\$12,500	11,628
\$15,000	13,954

Eligible Shareholders will not be obliged to pay brokerage or other fees in respect of New Shares acquired under the SPP (although Starpharma will pay certain professional and other fees to third parties). The SPP provides an opportunity for all Eligible Shareholders to increase their shareholding in a low cost way.

4. Use of funds and effect of the Offer

The proceeds of the Offer and the Placement will be used as follows:

Activity	
1. Accelerate two VivaGel® Bacterial Vaginosis Phase 3 Programs, file NDA and negotiate late stage licence	\$16 million
2. Advance Internal Drug Delivery Program into clinical development	\$8.5 million
3. Accelerate Agrochemical & Other Programs	\$5 million
4. Working Capital	\$5.5 million
Total (\$32 million Placement and \$3 million SPP)	\$35.0 million

The effect of the Offer will be to increase the number of Shares on issue and increase the cash held by Starpharma, the extent of which will depend on Applications received for New Shares. Starpharma has not set a minimum amount to be raised under the SPP and the Offer is not underwritten.

5. Participation is optional

Participation in the SPP is entirely optional (subject to the eligibility criteria set out in section 6). The Offer to acquire New Shares under the SPP is not a recommendation. If you are in any doubt about this Offer, including whether you should participate in the SPP or how such participation will affect you, you should consider seeking independent financial and taxation advice before making a decision as to whether or not to accept this Offer.

You should be aware that the price you pay for New Shares under the SPP may either be higher or lower than the market price of Starpharma Shares on the date New Shares are allotted and issued to you under the SPP. This means that the market value of the New Shares when they are issued to you may be less than the price you paid for them.

Starpharma recommends that you monitor the Share price, which can be found in the financial pages of major Australian metropolitan newspapers, or on the ASX website at www.asx.com.au (ASX code: SPL).

6. The Offer and eligibility

A person will be eligible to participate in the Offer (an **Eligible Shareholder**) if:

- (1) the person was a registered holder of Shares at 7:00pm (AEDT) on 15 November 2011 (**Record Date**); and
- (2) the person's registered address is in Australia or New Zealand.

Starpharma has determined that it is not practical for holders of Shares with registered addresses in other jurisdictions to participate in the SPP. To the extent that a person holds Shares on behalf of another person resident outside Australia or New Zealand, it is that person's responsibility to ensure that any acceptance complies with all applicable foreign laws.

The New Shares to be issued under this SPP have not been and will not be registered under the Securities Act, or the securities laws of any state or other jurisdiction of the United States. In order to comply with relevant securities laws, the New Shares to be issued under this SPP may not be offered to shareholders located in the United States or to shareholders who are, or who are acting for the account or benefit of, U.S. Persons.

Accordingly, you must not send copies of this Offer Document or any other material relating to the SPP to any person resident in the United States or who is, or is acting for the account or benefit of, U.S. Persons. You may not submit any completed Application Forms for any person resident in the United States or who is, or is acting for the account or benefit of, U.S. Persons. Failure to comply with these restrictions may result in violations of applicable securities laws.

7. Scale-back and shortfall

The SPP will be capped at \$3 million and Starpharma will scale back all Applications if they exceed \$3 million in aggregate. If Applications are scaled back, Starpharma reserves the right to undertake the scale back in any manner it considers fit.

If Starpharma exercises its right to scale back Applications, the amount of your Application as scaled back may not be equal to a whole number of New Shares. In that event, the number of New Shares allotted to you will be rounded up to the nearest whole number of New Shares. The difference in Application Monies will be refunded by Starpharma, without interest, no later than 10 Business Days after the New Shares are issued.

The Board reserves the right to place any shortfall under the SPP at its discretion.

8. Applications

8.1 Method of Application

An Eligible Shareholder may apply for New Shares by either:

- (1) completing the attached Application Form and returning it to:

Starpharma 2011 Share Purchase Plan
c/o Computershare Investor Services Pty Limited
452 Johnston Street
Abbotsford VICTORIA 3067
AUSTRALIA

together with a cheque, bank draft or money order made payable to “*Starpharma Holdings Ltd – 2011 SPP*” for the appropriate Application Monies by no later than **5.00pm (AEDT) on the Closing Date**; or

- (2) making a BPAY[®] payment by using the specific Biller Code and unique Customer Reference Number (**CRN**) shown on your Application Form.

If you make your payment using BPAY[®], you do not need to return your Application Form. Payment must be received by no later than **5.00pm (AEDT) on the Closing Date**.

You should be aware that your own financial institution may implement earlier cut-off times with regard to electronic payment, and you should therefore take this into consideration when making payment.

It is your responsibility to ensure that funds submitted through BPAY[®] are received by **5.00 pm (AEDT) on the Closing Date.**

Starpharma may, but is not obliged to, accept Applications received after the Closing Date. If Starpharma does not accept an Application for any reason, Starpharma will refund any excess Application Monies to the Eligible Shareholder, without interest, no later than 10 Business Days after the New Shares are issued.

Applications may only be made for parcels of New Shares in the amounts listed in section 3 and on the Application Form. If the amount of the cheque, bank draft or money order tendered with your Application Form or paid via BPAY[®] is:

- (3) less than \$1,000, Starpharma will not allot any New Shares to you and will refund your Application Monies;
- (4) greater than \$15,000, subject to scale back, Starpharma will allot the maximum number of New Shares to you and will refund your excess Application Monies; or
- (5) for an amount between \$1,000 and \$15,000 that is not one of the designated Application amounts, subject to scale back, Starpharma will allot to you the number of New Shares that would have been allotted to you had you applied for the highest designated amount that is less than the amount of your cheque, bank draft, money order or your BPAY[®] payment, and will refund your excess Application Monies.

8.2 **Non-renounceable**

Each Offer is non-renounceable. An Eligible Shareholder may not transfer or otherwise deal with its right to apply for New Shares under the SPP.

8.3 **One offer per shareholder**

Subject to condition 8.5, an Eligible Shareholder is entitled to apply under one (and only one) Offer. Starpharma may refuse to accept any Application which Starpharma, or a person maintaining the register of members (**Register**) on behalf of Starpharma, believes will result in a person being issued New Shares under more than one Offer.

If you are recorded with one or more persons as the joint holder of a holding of Shares, that joint holding is considered to be a single registered holding for the purpose of the **SPP**. Joint holders are only entitled to participate in the **SPP** in respect of that single holding. If the same joint holders receive more than one Offer due to multiple holdings, the joint holders may only apply under one Offer.

8.4 **Certification by Eligible Shareholders**

By applying for New Shares under the Offer, each Eligible Shareholder certifies that the aggregate of the application price paid by it for:

- (1) New Shares the subject of this Offer; and
- (2) any other Shares applied for, or which the Eligible Shareholder has instructed a custodian, trustee or nominee to acquire on their behalf, under the SPP or any similar arrangement offered by Starpharma in the 12 months prior to the date of its Application,

does not exceed \$15,000.

The \$15,000 limit applies irrespective of the number of Shares the Eligible Shareholder holds on the Record Date. Starpharma reserves the right to reject any Application for New

Shares under this SPP to the extent it considers that the Application (whether alone or in conjunction with other Applications) does not comply with these requirements.

8.5 Applications by custodians, trustees and nominees

A custodian, trustee or nominee within the definition of “custodian” in CO 09/425 (**Custodian**) who holds Shares on account of one or more Eligible Shareholders (**Beneficiaries**) may apply for New Shares up to a maximum of \$15,000 worth of New Shares for each Beneficiary, provided that it certifies to Starpharma in writing the matters set out in condition 9 of CO 09/425. This certification has been incorporated in the Custodian Application Form prepared by our Share Registry.

Custodians should have received a Custodian Application Form via email from the Share Registry. Please contact the Share Registry on 1300 850 505 (within Australia) or +61 3 9415 4000 (outside Australia) if you are a Custodian and have not received a Custodian Application Form.

Custodians who wish to apply for New Shares on behalf of one or more Beneficiaries must, by no later than **5.00pm (AEDT) on the Closing Date**, complete a Custodian Application Form and submit it via email to custodians@computershare.com.au (in MS excel format) **and then return their original signed Custodian Application Form to:**

Starpharma 2011 Share Purchase Plan
c/o Computershare Investor Services Pty Limited
452 Johnston Street
Abbotsford VICTORIA 3067
AUSTRALIA

Payment by Custodians must be received by no later than **5.00pm (AEDT) on the Closing Date** by the Custodian either:

- (1) returning a cheque, bank draft or money order made payable to “Starpharma Holdings Ltd – 2011 SPP” with the Custodian Application Form; or
- (2) making a BPAY[®] payment using the specific Biller Code and unique Customer Reference Number (**CRN**) shown on the Application Form enclosed with this Offer Document (and in the manner described in condition 8.1(2)).

If a person holds Shares as a trustee or nominee for another person, but is not a Custodian for the purposes of CO 09/425, you cannot participate for a Beneficiary in the manner described above. In this case, the rules for multiple single holdings set out in condition 8.3 apply.

By applying for Shares on behalf of a Beneficiary, the Custodian warrants to Starpharma that it has the authority of the Beneficiary to do so. For the purposes of condition 6(2), the relevant address for determining an Eligible Shareholder is the address of the Custodian.

To the extent that a Custodian or a person holds shares on behalf of another person resident outside Australia or New Zealand, it is the Custodian’s responsibility to ensure that any acceptance complies with all applicable foreign laws.

9. Effect of Application

By applying for New Shares under an Offer, an Eligible Shareholder is taken to:

- (1) agree to be bound by the terms and conditions set out in this Offer Document, the Offer and the Application Form;

- (2) authorise Starpharma to place the Eligible Shareholder's name on Starpharma's Register in respect of those New Shares;
- (3) agree to be bound by Starpharma's constitution; and
- (4) provide the certification referred to in section 8.4 and, where applicable, the warranty in condition 8.5.

10. Rights attaching to New Shares

New Shares issued under the SPP will rank equally with all existing Shares and will carry the same voting rights, dividend rights and other entitlements at the date they are issued.

The New Shares are expected to be allotted under the SPP on 14 December 2011. Starpharma expects that the New Shares will be listed for quotation on ASX on 15 December 2011 and holding statements or issue notices in respect of the New Shares allotted under the SPP will be dispatched on 16 December 2011.

You should confirm your holding before trading in any New Shares you believe have been issued to you under the SPP. Any shareholder that sells New Shares before receiving confirmation of their holding in the form of their holding statement will do so at their own risk. Starpharma and the Share Registry disclaim all liability whether in negligence or otherwise (and to the maximum extent permitted by law) to persons who trade their New Shares before receiving their holding statements, whether on the basis of confirmation of the allocation provided by Starpharma or the Share Registry.

11. Alteration of terms

Starpharma may, in its discretion, vary, suspend or cancel the Offer at any time, subject to the Corporations Act, ASIC Class Orders, the Listing Rules and any other law or regulation to which Starpharma is subject.

A variation, suspension or cancellation does not give rise to any liability on the part of, or any action against, Starpharma or any member of the Board.

If the Board determines to suspend or cancel the SPP during the currency of an Offer, any application money received by Starpharma will be refunded to the Eligible Shareholder, without interest, as soon as reasonably practical after the suspension or cancellation and in any event within 10 Business Days after the Closing Date.

12. Offer document

In the absence of an exemption in the Corporations Act, ASIC class order or other ASIC relief, a person may not offer shares without lodging a disclosure document with ASIC.

ASIC has granted relief from the disclosure requirements in the Corporations Act under CO 09/425 for shares offered under a share purchase plan. This Offer meets the requirements of CO 09/425.

13. Definitions

Terms and abbreviations used in this Offer Document have the following meaning:


\$	Australian dollars
-----------	--------------------

AEDT	Australian Easter Daylight Savings Time
Application	A valid application made in accordance with condition 8.1
Application Form	The application form attached to this Offer Document
Application Monies	Monies paid by Eligible Shareholders in respect of New Shares applied for under the SPP.
ASIC	Australian Securities and Investments Commission
ASX	ASX Limited ABN 98 008 624 691
Board	The board of directors of Starpharma
Business day	Has the meaning given to that term in the Listing Rules
Closing Date	5:00pm (AEDT), 7 December 2011 (unless extended)
CO 09/425	ASIC Class Order [CO 09/425] <i>Share and interest purchase plans</i>
Constitution	The constitution of Starpharma as amended from time to time
Corporations Act	<i>Corporations Act 2001</i> (Cth)
Corporations Regulations	<i>Corporations Regulations 2001</i> (Cth)
Director	A director of Starpharma
Eligible Shareholder	A person who meets the requirements of section 6
Listing Rules	The ASX Listing Rules
New Share	A Share to be issued pursuant to the Offer
Offer	The offer of New Shares under this Offer Document
Securities Act	<i>Securities Act of 1933</i> of the USA
Share	A fully paid ordinary share in Starpharma
Share Registry	Computershare Investor Services Pty Limited
US Person	Has the meaning given to that term in Regulation S of the Securities Act
United States	Has the meaning given to that term in Regulation S of the Securities Act

For all enquiries:

Phone:
(within Australia) 1300 850 505
(outside Australia) 61 3 9415 4000

Web:
 www.investorcentre.com/contact



000001 000 SPL
MR SAM SAMPLE
123 SAMPLE STREET
SAMPLETOWN VIC 3000

Make your payment:



See over for details of the Offer and how to make your payment

Share Purchase Plan Application Form

 **Your payment must be received by 5:00pm (AEDT) 7 December 2011**

This is an important document that requires your immediate attention.

It can only be used in relation to the Share holding represented by the details printed overleaf. If you are in doubt about how to deal with this form, please contact your financial or other professional adviser.

By making payment you agree to be bound by the constitution of Starpharma and that the submission of that payment constitutes an irrevocable offer by you to subscribe for New Shares on the terms of the SPP.

CERTIFICATION

By submitting the slip below and applying for New Shares under the SPP you certify that the aggregate of the application price paid by you for:

- the New Shares the subject of your Application; and
- any other Shares applied for by you, or which you have instructed a custodian, trustee or nominee to acquire on your behalf, under the SPP or any similar arrangement offered by Starpharma in the 12 months prior to the date of submission of the slip below,

does not exceed A\$15,000.

Starpharma may make any determination in connection with the SPP, including refusing to accept any Application for New Shares, in any manner it thinks fit.

Any determination by Starpharma will be conclusive and binding on all Eligible Shareholders and other persons to whom the determination relates. Starpharma reserves the right to waive strict compliance with any provision of the SPP Offer Document, to amend or vary the terms and conditions of the SPP or to suspend or terminate the SPP at any time. Any such amendment, suspension or termination will be binding on all Eligible Shareholders even where Starpharma does not notify you of that event.

Step 1: Registration Name

Please check the details provided and update your address via www.investorcentre.com if any of the details are incorrect.

Step 2: Make Your Payment

Note that Applications for New Shares must only be made in the amount set out in this slip. Starpharma will deal with Applications that are not made in these amounts in accordance with condition 8.1 of the SPP Offer Document. Note that the amount chosen may be subject to scale back in accordance with the terms of the SPP.

Choose one of the payment methods shown below.

BPAY®: Using the specific Biller Code and Unique Customer Reference Number overleaf. Do not return the slip with **BPAY** payment.

By Mail: Complete the reverse side of this payment slip and detach and return with your payment. Make your cheque, bank draft or money order payable in Australian dollars to "Starpharma Holdings Limited - 2011 SPP" and crossed "Not Negotiable". The cheque must be drawn from an Australian bank. Cash is not accepted. Payment will be processed on the day of receipt. Receipts will not be forwarded. Funds cannot be debited directly from your account.

Entering your contact details is not compulsory, but will assist us if we need to contact you.

Turn over for details of the Offer →

Starpharma Holdings Limited
Share Purchase Plan Application Form
Payment must be received by 5:00pm (AEDT) 7 December 2011


Share Purchase Plan Application Form

X 9999999991

I ND

STEP 1

Registration Name & Offer Details

 For your security keep your SRN/
HIN confidential.

Registration Name: MR SAM SAMPLE
123 SAMPLE STREET
SAMPLETOWN VIC 3000

Entitlement No: 00005856

Offer Details: Record date: **7.00pm (AEDT) 15 November 2011**

Minimum value available to purchase: **\$1,000**

Maximum value available to purchase: **\$15,000**

STEP 2

Make Your Payment



Billers Code: 193342
Ref No: 1234 5678 9123 4567 89

Contact your financial institution to make your payment from your cheque or savings account.

Pay by Mail:



Make your cheque, money order or bank draft payable to Starpharma Holdings Limited.

Return your cheque with the below slip to:
Computershare Investor Services Pty Limited
GPO BOX 505 Melbourne Victoria 3001 Australia

Privacy Statement

Personal information is collected on this form by Computershare Investor Services Pty Limited (CIS) as registrar for Starpharma, for the purpose of maintaining registers of securityholders, facilitating distribution payments and other corporate actions and communications. Your personal information may be disclosed to CIS's related bodies corporate, to external service companies such as print or mail service providers, or as otherwise permitted by law. If you would like details of your personal information held by CIS, or you would like to correct information that is inaccurate, incorrect or out of date, please contact CIS. In accordance with the Corporations Act 2001, you may be sent material (including marketing material) approved by Starpharma in addition to general corporate communications. You may elect not to receive marketing material by contacting CIS using the details provided above or email privacy@computershare.com.au

Purchase Details for Starpharma Holdings Limited (choose one option)

- \$1,000 worth of New Shares OR \$2,500 worth of New Shares OR \$5,000 worth of New Shares
- \$7,500 worth of New Shares OR \$10,000 worth of New Shares OR \$12,500 worth of New Shares
- \$15,000 worth of New Shares



Entitlement No: 00005856

MR SAM SAMPLE
123 SAMPLE STREET
SAMPLETOWN VIC 3000

Payment must be received by 5:00pm (AEDT) 7 December 2011

Contact Details

Contact Name _____ Daytime Telephone _____

Cheque Details

Drawer	Cheque Number	BSB Number	Account Number	Amount of Cheque
				A\$

123456789123456789+0000000001-3051+14